Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

European Innovation Council · Finished

CelerisTx - Celeris One Platform Closed-loop deep learning in early-stage drug discovery - cloud platform for targeted protein degradation

Coordinator
Celeris Therapeutics GmbH, Austria
Runs
1 July 2022 to 29 February 2024
Status
Finished
EU funding
€2.5m
Total cost
€4.9m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190126641

What the project is doing

In the project's own words, from its summary on CORDIS.

Celeris Therapeutics is a deep learning company that uses innovative, in-silico methods such as geometric deep learning and graph neural networks to degrade currently undruggable targets (pathogenic proteins). The platform shall make a broad impact by addressing currently incureable diseases such as Alzheimer's, Parkinson's, and different types of cancer like breast and prostate cancer. Celeris Therapeutics' technical solution is the web application (orchestration platform) Celeris One.

It consists of three modules: Hades (target ID), Xanthos (predicting biomolecular interactions and ligand design), Hephaistos (automated synthesize and validate). The addressed market is in the early-stage drug discovery and users are pharmaceutical and biotech companies with a focus on Targeted Protein Degradation. The targeted customers are med. and comp. chemists, that currently rely on docking, which is computationally intensive, slow and inaccurate compared to CelerisTx deep learning methods.

Topics

Who is involved

OrganisationCityCountryRole
Celeris Therapeutics GmbHGrazAustriaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI